Lung cancer in never smokers

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 1, 2011, Pages 10-21

  Yang, Ping ^a  

^a Mayo Clinic   (United States)

Author keywords

environmental risk factors; genetic predisposition; Lung cancer; molecular target therapy; never smokers

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBOPLATIN; CARCINOGEN; CAROTENOID; CETUXIMAB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; GLUTATHIONE TRANSFERASE P1; HEAT SHOCK PROTEIN 90 INHIBITOR; ISOFLAVONE; K RAS PROTEIN; MEMBRANE PROTEIN; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; RADON; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOL; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN RECEPTOR;

AFRICA; AFRICAN AMERICAN; ARTICLE; ASIAN; BIOMASS; BUTTER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; CHLAMYDOPHILA PNEUMONIAE; CHROMOSOME 17P; CHROMOSOME 3P; CHROMOSOME 5Q; CHROMOSOME 9P; CHRONIC BRONCHITIS; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL ASSESSMENT; DIET; ENVIRONMENTAL EXPOSURE; EPITHELIAL MESENCHYMAL TRANSITION; EPSTEIN BARR VIRUS; FOOD INTAKE; FRUIT; GENE DOSAGE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPE PHENOTYPE CORRELATION; GEOGRAPHIC DISTRIBUTION; HELICOBACTER PYLORI; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPONATREMIA; INDIA; INDOOR AIR POLLUTION; IONIZING RADIATION; LIFESTYLE; LIVER TOXICITY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG CANCER IN NEVER SMOKER; LUNG CARCINOGENESIS; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG INFECTION; LUNG NON SMALL CELL CANCER; MENTAL HEALTH; METASTASIS; MICROSPORUM CANIS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OCCUPATIONAL EXPOSURE; ORAL CONTRACEPTION; OVERALL SURVIVAL; PANDEMIC; PASSIVE SMOKING; PHYSICAL ACTIVITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PSYCHOLOGICAL ASPECT; PUBLICATION; RED MEAT; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SALVAGE THERAPY; SEPSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; SOCIAL ASPECT; SUPPLEMENTATION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULOSIS; TUMOR GENE; UNITED STATES; VEGETABLE; VIRUS INFECTION; WHOLE BRAIN RADIATION THERAPY; WINE;

COMMUNICABLE DISEASES; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; LIFE STYLE; LUNG DISEASES; LUNG NEOPLASMS; RISK FACTORS;

EID: 79954570724     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1272865     Document Type: Article

References (161)

1. Subramanian J, Govindan R. Lung cancer in never-smokers': a unique entity. Oncology (Williston Park) 2010 24 1 29-35
2. Rudin C M., Avila-Tang E, Samet J M. Lung cancer in never smokers: a call to action. Clin Cancer Res 2009 15 18 5622-5625
3. Samet J M., Avila-Tang E, Boffetta P et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 2009 15 18 5626-5645
4. Sun S, Schiller J H., Gazdar A F. Lung cancer in never smokersa different disease. Nat Rev Cancer 2007 7 10 778-790 (Pubitemid 47463669)
5. Scagliotti G V., Longo M, Novello S. Nonsmall cell lung cancer in never smokers. Curr Opin Oncol 2009 21 2 99-104
6. Lung cancer. http://en.wikipedia.org/wiki/Lung-cancer#cite-note- AUTOREF27-140
7. Morgagni G B. De sedibus et causis morborum per anatomen indagatis. 1761. http://en.wikipedia.org/wiki/Lung-cancer#cite-note-AUTOREF27-140
8. Bayle G L. Recherches sur la phtisie pulmonaire. Paris, France: 1810. http://en.wikipedia.org/wiki/Lung-cancer#cite-ref-AUTOREF28-141-0
9. Fried B M. Primary carcinoma of the lung. Bronchiogenic cancer: a clinical and pathological study. Medicine 1931 10 373-508
10. Karsner H T., Saphir O. Small cell carcinomas of the lung. Am J Pathol 1930 6 5 553-562, 3
11. Weller C V. The pathology of primary carcinoma of the lung. Archives of Pathology 1929 7 478-519
12. Rosenblatt M B., Lisa J R. Bronchial adenoma. In: Cancer of the Lung: Pathology, Diagnosis, and Treatment. New York Oxford University Press 1956 259-312
13. United States Surgeon General's Advisory Committee on Smoking and Health. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC U.S. Department of Health, Education and Welfare, Public Health Service, Government Printing Office 1964 19-21
14. Wakelee H A., Chang E T., Gomez S L. et al. Lung cancer incidence in never smokers. J Clin Oncol 2007 25 5 472-478 (Pubitemid 350002951)
15. Johansson M, Relton C, Ueland P M. et al. Serum B vitamin levels and risk of lung cancer. JAMA 2010 303 23 2377-2385
16. Subramanian J, Morgensztern D, Goodgame B et al. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol 2010 5 1 23-28
17. National Research Council (NRC) Committee on the Biological Effects of Ionizing Radiations, Board on Radiation Effects Research, Commission on Life Sciences, ed. Health Risks of Radon and Other Internally Deposited Alpha-Emitters: BEIR. Washington National Academy Press 1988
18. Harting F, Hesse W. Der Lungenkrebs, die Bergkrankheit in den schneeberger Gruben. Viertel Gerichtl Med Oeff Sanitaetswes 1879 31 102-132 313-337
19. Samet J M. Indoor radon levels may be higher than in uranium mines. Radon and lung cancer: how great is the risk? J Respir Dis 1989 10 73-83
20. Archer V E., Wagoner J K., Lundin F E. Lung cancer among uranium miners in the United States. Health Phys 1973 25 4 351-371
21. Samet J M., Kutvirt D M., Waxweiler R J., Key C R. Uranium mining and lung cancer in Navajo men. N Engl J Med 1984 310 23 1481-1484 (Pubitemid 14108843)
22. Gilliland F D., Hunt W C., Archer V E., Saccomanno G. Radon progeny exposure and lung cancer risk among non-smoking uranium miners. Health Phys 2000 79 4 365-372
23. Al-Zoughool M, Krewski D. Health effects of radon: a review of the literature. Int J Radiat Biol 2009 85 1 57-69
24. United States Environmental Protection Agency. Respiratory Health Effects of Passive Smoking: Lung Cancer and Other Disorders. EPA/600/606-690/006F. Washington, DC U.S. Environmental Protection Agency, Office of Research and Development 1992
25. Yang P, Sun Z, Krowka M J. et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 2008 168 10 1097-1103 (Pubitemid 351749227)
26. Zatloukal P, Kubík A, Pauk N, Tomásek L, Petruzelka L. Adenocarcinoma of the lung among women: risk associated with smoking, prior lung disease, diet and menstrual and pregnancy history. Lung Cancer 2003 41 3 283-293 (Pubitemid 36970184)
27. Thun M J., Henley S J., Burns D, Jemal A, Shanks T G., Calle E E. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 2006 98 10 691-699 (Pubitemid 43832505)
28. National Research Council (NRC), Committee on Health Risks of Exposure to Radon, Board on Radiation Effects Research, Commission on Life Sciences, ed. Health Effects of Exposure to Radon. (BEIR IV.) Washington. National Academy Press 1999
29. Lam W K. Lung cancer in Asian women: the environment and genes. Respirology 2005 10 4 408-417 (Pubitemid 43942608)
30. Schmid K, Kuwert T, Drexler H. Radon in indoor spaces: an underestimated risk factor for lung cancer in environmental medicine. Dtsch Arztebl Int 2010 107 11 181-186
31. Guha N, Merletti F, Steenland N K., Altieri A, Cogliano V, Straif K. Lung cancer risk in painters: a meta-analysis. Environ Health Perspect 2010 118 3 303-312
32. Harris J M., Johnston I D., Rudd R, Taylor A J., Cullinan P. Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax 2010 65 1 70-76
33. Liu Z Y., He X Z., Chapman R S. Smoking and other risk factors for lung cancer in Xuanwei, China. Int J Epidemiol 1991 20 1 26-31
34. Daniels C E., Jett J R. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 2005 11 5 431-437 (Pubitemid 41291088)
35. Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 2007 101 12 2534-2540 (Pubitemid 47618391)
36. Mizushima Y, Kobayashi M. Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. Chest 1995 108 5 1272-1277
37. Yousem S A. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990 21 5 467-474 (Pubitemid 20165139)
38. Brenner D R., Hung R J., Tsao M S. et al. Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. BMC Cancer 2010 10 285
39. Cheng Y W., Chiou H L., Chen J T. et al. Gender difference in human papillomarvirus infection for non-small cell lung cancer in Taiwan. Lung Cancer 2004 46 2 165-170
40. Engels E A., Brock M V., Chen J, Hooker C M., Gillison M, Moore R D. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006 24 9 1383-1388 (Pubitemid 46622002)
41. Kirk G D., Merlo C, O' Driscoll P et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007 45 1 103-110 (Pubitemid 46984625)
42. Laurila A L., Anttila T, Läärä E et al. Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer. Int J Cancer 1997 74 1 31-34 (Pubitemid 27157852)
43. Littman A J., White E, Jackson L A. et al. Chlamydia pneumoniae infection and risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2004 13 10 1624-1630 (Pubitemid 39331884)
44. Smith J S., Kumlin U, Nyberg F et al. Lack of association between serum antibodies of Chlamydia pneumoniae infection and the risk of lung cancer. Int J Cancer 2008 123 10 2469-2471
45. Hinds M W., Cohen H I., Kolonel L N. Tuberculosis and lung cancer risk in nonsmoking women. Am Rev Respir Dis 1982 125 6 776-778 (Pubitemid 12074601)
46. Lim W T., Chuah K L., Leong S S., Tan E H., Toh C K. Assessment of human papillomavirus and Epstein-Barr virus in lung adenocarcinoma. Oncol Rep 2009 21 4 971-975
47. Paulus J K., Asomaning K, Kraft P, Johnson B E., Lin X, Christiani D C. Parity and risk of lung cancer in women. Am J Epidemiol 2010 171 5 557-563
48. Kabat G C., Miller A B., Rohan T E. Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. Int J Cancer 2007 120 10 2214-2220 (Pubitemid 46555861)
49. Liu Y, Inoue M, Sobue T, Tsugane S. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer 2005 117 4 662-666 (Pubitemid 41504556)
50. Hampton T. Lung cancer mortality higher in women who used combination hormone therapy. JAMA 2009 302 6 615-616
51. Elliott A M., Hannaford P C. Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception 2006 73 4 331-335 (Pubitemid 43375089)
52. Benowitz N L., Lessov-Schlaggar C N., Swan G E., Jacob P III. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 2006 79 5 480-488
53. Key T J., Allen N E., Spencer E A., Travis R C. The effect of diet on risk of cancer. Lancet 2002 360 9336 861-868 (Pubitemid 35257961)
54. World Cancer Research Fund International. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC American Institute for Cancer Research 2007
55. Mulder I, Jansen M C., Smit H A. et al, Seven Countries Study Research Group. Role of smoking and diet in the cross-cultural variation in lung-cancer mortality: the Seven Countries Study. Int J Cancer 2000 88 4 665-671
56. Liu Y, Sobue T, Otani T, Tsugane S. Vegetables, fruit consumption and risk of lung cancer among middle-aged Japanese men and women: JPHC study. Cancer Causes Control 2004 15 4 349-357 (Pubitemid 38988024)
57. Shimazu T, Inoue M, Sasazuki S et al, Japan Public Health Center-based Prospective Study Group. Isoflavone intake and risk of lung cancer: a prospective cohort study in Japan. Am J Clin Nutr 2010 91 3 722-728
58. Leitzmann M F., Koebnick C, Abnet C C. et al. Prospective study of physical activity and lung cancer by histologic type in current, former, and never smokers. Am J Epidemiol 2009 169 5 542-553
59. Yun Y H., Lim M K., Won Y J. et al. Dietary preference, physical activity, and cancer risk in men: national health insurance corporation study. BMC Cancer 2008 8 366
60. Sinner P, Folsom A R., Harnack L, Eberly L E., Schmitz K H. The association of physical activity with lung cancer incidence in a cohort of older women: the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2006 15 12 2359-2363 (Pubitemid 46048291)
61. Sui X, Lee D C., Matthews C E. et al. Influence of cardiorespiratory fitness on lung cancer mortality. Med Sci Sports Exerc 2010 42 5 872-878
62. Alberg A J., Ford J G., Samet J M., American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007 132 3, suppl 29S-55S (Pubitemid 47502798)
63. Devesa S S., Bray F, Vizcaino A P., Parkin D M. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005 117 2 294-299 (Pubitemid 41379403)
64. Hoffmann D, Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health 1997 50 4 307-364
65. Schneiderman M A., Davis D L., Wagener D K. Lung cancer that is not attributable to smoking. JAMA 1989 261 18 2635-2636
66. Liam C K., Pang Y K., Leow C H., Poosparajah S, Menon A. Changes in the distribution of lung cancer cell types and patient demography in a developing multiracial Asian country: experience of a university teaching hospital. Lung Cancer 2006 53 1 23-30 (Pubitemid 43831361)
67. de Andrade M, Ebbert J O., Wampfler J A. et al. Environmental tobacco smoke exposure in women with lung cancer. Lung Cancer 2004 43 2 127-134 (Pubitemid 38114740)
68. Ebbert J O., Chhatwani L, Aubry M C. et al. Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions. J Thorac Oncol 2010 5 8 1213-1220
69. Yang P, Cerhan J R., Vierkant R A. et al. Adenocarcinoma of the lung is strongly associated with cigarette smoking: further evidence from a prospective study of women. Am J Epidemiol 2002 156 12 1114-1122 (Pubitemid 35453682)
70. Raz D J., He B, Rosell R, Jablons D M. Bronchioloalveolar carcinoma: a review. Clin Lung Cancer 2006 7 5 313-322 (Pubitemid 43950978)
71. Laskin J J., Sandler A B., Johnson D H. Redefining bronchioloalveolar carcinoma. Semin Oncol 2005 32 3 329-335 (Pubitemid 40834489)
72. Travis W D., Colby T V., Shimosato Y et al. Histological Typing of Lung and Pleural Tumours. 3rd ed. New York Springer-Verlag 1999 21-47
73. Gao P, Yang X, Xue Y W. et al. Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression. Cancer 2009 115 14 3222-3232
74. Kubo T, Yamamoto H, Ichimura K et al. DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components. Lung Cancer 2009 65 3 328-332
75. Rusch V W., Reuter V E., Kris M G. et al. Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. J Thorac Cardiovasc Surg 1992 104 5 1465-1469
76. Marchetti A, Buttitta F, Pellegrini S et al. Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol 1996 179 3 254-259 (Pubitemid 26266402)
77. Holst V A., Finkelstein S, Yousem S A. Bronchioloalveolar adenocarcinoma of lung: monoclonal origin for multifocal disease. Am J Surg Pathol 1998 22 11 1343-1350 (Pubitemid 28499124)
78. Yamasaki M, Takeshima Y, Fujii S, Matsuura M, Tagawa K, Inai K. Correlation between morphological heterogeneity and genetic alteration within one tumor in adenocarcinomas of the lung. Pathol Int 2000 50 11 891-896
79. Yamasaki M, Takeshima Y, Fujii S et al. Correlation between genetic alterations and histopathological subtypes in bronchiolo-alveolar carcinoma and atypical adenomatous hyperplasia of the lung. Pathol Int 2000 50 10 778-785
80. Gandara D R., West H, Chansky K et al. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res 2004 10 12 Pt 2 4205s-4209s (Pubitemid 38812447)
81. Wislez M, Beer D G., Wistuba I, Cadranel J, Saijo N, Johnson B E. Molecular biology, genomics, and proteomics in bronchioloalveolar carcinoma. J Thorac Oncol 2006 1 9, suppl S8-S12 (Pubitemid 47181352)
82. Sakuma Y, Matsukuma S, Yoshihara M et al. Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. Mod Pathol 2007 20 9 967-973 (Pubitemid 47267825)
83. Dacic S, Sasatomi E, Swalsky P A., Kim D W., Finkelstein S D., Yousem S A. Loss of heterozygosity patterns of sclerosing hemangioma of the lung and bronchioloalveolar carcinoma indicate a similar molecular pathogenesis. Arch Pathol Lab Med 2004 128 8 880-884 (Pubitemid 39014120)
84. Toonkel R L., Borczuk A C., Powell C A. TGF-beta signaling pathway in lung adenocarcinoma invasion. J Thorac Oncol 2010 5 2 153-157
85. Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med 2010 134 1 66-72
86. Ahn M J., Lee J, Park Y H. et al. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. J Thorac Oncol 2010 5 8 1185-1196
87. Kawaguchi T, Matsumura A, Fukai S et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 2010 5 7 1001-1010
88. Kawaguchi T, Takada M, Kubo A et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010 5 5 620-630
89. Meguid R A., Hooker C M., Harris J et al. Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers. Chest 2010 138 3 500-509
90. Riely G J. Lung cancer in 'Never-smokers': molecular factors trump risk factors. Oncology (Williston Park) 2010 24 1 38-40
91. Doran E, Jackman D. Fire without smoke: lung cancer in 'never-smokers'. Oncology (Williston Park) 2010 24 1 40-43
92. Burns T F., Rudin C M. Lung cancer in never-smokers': beyond EGFR mutations and EGFR-TK inhibitors. Oncology (Williston Park) 2010 24 1 48-49
93. Kawaguchi T, Takada M, Kubo A et al. Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan. J Thorac Oncol 2010 5 7 1011-1017
94. Jian G, Songwen Z, Ling Z et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2010 136 9 1341-1347
95. Faehling M, Eckert R, Kuom S, Kamp T, Stoiber K M., Schumann C. Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology 2010 78 3-4 249-258
96. Reck M. A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond. Expert Rev Anticancer Ther 2010 10 6 955-965
97. Campbell L, Blackhall F, Thatcher N. Gefitinib for the treatment of non-small-cell lung cancer. Expert Opin Pharmacother 2010 11 8 1343-1357
98. Kono S A., Marshall M E., Ware K E., Heasley L E. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat 2009 12 4-5 95-102
99. Eisenhauer E A., Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009 45 2 228-247
100. Jackman D, Pao W, Riely G J. et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010 28 2 357-360
101. Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 2007 96 6 857-863 (Pubitemid 46452294)
102. Asahina H, Yamazaki K, Kinoshita I, Yokouchi H, Dosaka-Akita H, Nishimura M. Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. Lung Cancer 2006 54 3 419-422 (Pubitemid 44634147)
103. Marchetti A, Milella M, Felicioni L et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009 11 10 1084-1092
104. Rho J K., Choi Y J., Lee J K. et al. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Mol Cancer Res 2009 7 10 1736-1743
105. Chen H J., Mok T S., Chen Z H. et al. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res 2009 15 4 651-658
106. Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, Oyama T. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 2010 30 7 2513-2517
107. Zhang W, Stabile L P., Keohavong P et al. Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. J Thorac Oncol 2006 1 7 635-647 (Pubitemid 47163950)
108. Kook E H., Kim Y M., Kim H T. et al. Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib. Oncol Res 2010 18 9 445-451
109. Ullrich R T., Zander T, Neumaier B et al. Early detection of erlotinib treatment response in NSCLC by 3-deoxy-3-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS ONE 2008 3 12 e3908
110. Wong M K., Lo A I., Lam B, Lam W K., Ip M S., Ho J C. Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 2010 65 6 1023-1028
111. Costa D B., Nguyen K S., Cho B C. et al. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008 14 21 7060-7067
112. Kuo C H., Lin S M., Lee K Y. et al. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance. Clin Lung Cancer 2010 11 1 51-56
113. Manson G V., Ma P C. Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib. Clin Lung Cancer 2010 11 1 57-60
114. Tang Z, Du R, Jiang S et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 2008 99 6 911-922
115. Regales L, Gong Y, Shen R et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009 119 10 3000-3010
116. Sawai A, Chandarlapaty S, Greulich H et al. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 2008 68 2 589-596 (Pubitemid 351380088)
117. Kim J E., Lee D H., Choi Y et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009 65 3 351-354
118. Olmez I, Donahue B R., Butler J S., Huang Y, Rubin P, Xu Y. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung Cancer 2010 70 2 174-179
119. Lee Y J., Shim H S., Kang Y A. et al. Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. J Cancer Res Clin Oncol 2010 136 12 1937-1944
120. Soda M, Choi Y L., Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007 448 7153 561-566 (Pubitemid 47206930)
121. Sasaki T, Rodig S J., Chirieac L R., Jänne P A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010 46 10 1773-1780
122. Zhang X, Zhang S, Yang X et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010 9 188
123. Takahashi T, Sonobe M, Kobayashi M et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010 17 3 889-897
124. Shaw A T., Yeap B Y., Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009 27 26 4247-4253
125. Yang P, Oliveira A, Wampfler J et al. Reduced disease-free survival associated with anaplastic lymphoma kinase translocation (ALK +) in lung adenocarcinoma patients with no cigarette smoking history. Paper presented at: American Society for Radiation Oncology; December 9-10, 2010; Chicago, IL
126. Neal J W., Sequist L V. Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol 2010 11 1-2 36-44
127. Raleigh Z T. A biopsychosocial perspective on the experience of lung cancer. J Psychosoc Oncol 2010 28 1 116-125
128. Gorlova O Y., Weng S F., Zhang Y, Amos C I., Spitz M R. Aggregation of cancer among relatives of never-smoking lung cancer patients. Int J Cancer 2007 121 1 111-118 (Pubitemid 46753858)
129. Broderick P, Wang Y, Vijayakrishnan J et al. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res 2009 69 16 6633-6641
130. Bailey-Wilson J E., Amos C I., Pinney S M. et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet 2004 75 3 460-474 (Pubitemid 39095821)
131. Amos C I., Pinney S M., Li Y et al. A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. Cancer Res 2010 70 6 2359-2367
132. You M, Wang D, Liu P et al. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res 2009 15 8 2666-2674
133. Wang M, Vikis H G., Wang Y et al. Identification of a novel tumor suppressor gene p34 on human chromosome 6q25.1. Cancer Res 2007 67 1 93-99 (Pubitemid 46142763)
134. Amos C I., Wu X, Broderick P et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008 40 5 616-622 (Pubitemid 351601203)
135. Hung R J., McKay J D., Gaborieau V et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008 452 7187 633-637 (Pubitemid 351483367)
136. Liu P, Vikis H G., Wang D et al. Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst 2008 100 18 1326-1330
137. McKay J D., Hung R J., Gaborieau V et al, EPIC Study. Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008 40 12 1404-1406
138. Rafnar T, Sulem P, Stacey S N. et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009 41 2 221-227
139. Spitz M R., Amos C I., Dong Q, Lin J, Wu X. The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst 2008 100 21 1552-1556
140. Thorgeirsson T E., Geller F, Sulem P et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008 452 7187 638-642 (Pubitemid 351483366)
141. Wang Y, Broderick P, Webb E et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008 40 12 1407-1409
142. Yang P, Li Y, Jiang R et al. A rigorous and comprehensive validation: common genetic variations and lung cancer. Cancer Epidemiol Biomarkers Prev 2010 19 1 240-244
143. Li Y, Sheu C C., Ye Y et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 2010 11 4 321-330
144. Landi M T., Chatterjee N, Caporaso N E. et al. GPC5 rs2352028 variant and risk of lung cancer in never smokers. Lancet Oncol 2010 11 8 714-716
145. Yang P, Jen J, Li Y et al. Lancet Oncol. 2010 11 716, authors' reply
146. Veugelers M, Vermeesch J, Reekmans G, Steinfeld R, Marynen P, David G. Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family. Genomics 1997 40 1 24-30 (Pubitemid 27108243)
147. Blackhall F H., Merry C L., Davies E J., Jayson G C. Heparan sulfate proteoglycans and cancer. Br J Cancer 2001 85 8 1094-1098 (Pubitemid 33052304)
148. Yang P, Ebbert J O., Sun Z, Weinshilboum R M. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 2006 24 11 1761-1769 (Pubitemid 46622148)
149. Kiyohara C, Wakai K, Mikami H, Sido K, Ando M, Ohno Y. Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: a case-control study in Japanese nonsmoking women. Int J Cancer 2003 107 1 139-144 (Pubitemid 37100098)
150. Bennett W P., Alavanja M C., Blomeke B et al. Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J Natl Cancer Inst 1999 91 23 2009-2014
151. Weinberg C R., Sandler D P. Gene-by-environment interaction for passive smoking and glutathione S-transferase M1? J Natl Cancer Inst 1999 91 23 1985-1986
152. Nyberg F, Hou S M., Hemminki K, Lambert B, Pershagen G. Glutathione S-transferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls. Cancer Epidemiol Biomarkers Prev 1998 7 10 875-883 (Pubitemid 28471575)
153. Zhou W, Liu G, Miller D P. et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2003 12 4 359-365 (Pubitemid 36427997)
154. Yin J, Li J, Ma Y, Guo L, Wang H, Vogel U. The DNA repair gene ERCC2/XPD polymorphism Arg 156Arg (A22541C) and risk of lung cancer in a Chinese population. Cancer Lett 2005 223 2 219-226 (Pubitemid 40719620)
155. Cohet C, Borel S, Nyberg F et al. Exon 5 polymorphisms in the O6-alkylguanine DNA alkyltransferase gene and lung cancer risk in non-smokers exposed to second-hand smoke. Cancer Epidemiol Biomarkers Prev 2004 13 2 320-323 (Pubitemid 38222567)
156. Vogel U, Christensen J, Wallin H et al. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res 2008 639 1-2 89-100
157. Olivo-Marston S E., Yang P, Mechanic L E. et al. Childhood exposure to secondhand smoke and functional mannose binding lectin polymorphisms are associated with increased lung cancer risk. Cancer Epidemiol Biomarkers Prev 2009 18 12 3375-3383
158. Shen M, Vermeulen R, Rajaraman P et al. Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China. Environ Mol Mutagen 2009 50 4 285-290
159. Lee K M., Shen M, Chapman R S. et al. Polymorphisms in immunoregulatory genes, smoky coal exposure and lung cancer risk in Xuan Wei, China. Carcinogenesis 2007 28 7 1437-1441 (Pubitemid 47243537)
160. Wang L I., Neuberg D, Christiani D C. Asbestos exposure, manganese superoxide dismutase (MnSOD) genotype, and lung cancer risk. J Occup Environ Med 2004 46 6 556-564 (Pubitemid 38747701)
161. Senn O, Russi E W., Imboden M, Probst-Hensch N M. alpha1-Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants. Eur Respir J 2005 26 5 909-917 (Pubitemid 41632051)